Otomycosis

Summary

Otomycosis (MONDO:0000262) is a disease and 15 clinical trials. Top therapeutic interventions include clotrimazole, miconazole, and povidone-iodine. A subtype of otitis externa — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	otomycosis
Mondo ID	MONDO:0000262
MeSH	D059249
DOID	DOID:0050147
ICD-11	107388709
SNOMED CT	53316003
UMLS	C0029895
MedGen	452110
Anatomy (UBERON)	UBERON:0001691
Is cancer (heuristic)	no

Also known as: external ear fungal infectious disease · otitis mycotic externa

Disease family

This is a subtype of otitis externa. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › external ear disorder › otitis externa › otomycosis

Related subtypes (3): malignant otitis externa, acute otitis externa, perichondritis of auricle

Subtypes (1): chronic fungal otitis externa

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Clotrimazole	Phase 3 (in late-stage trials)
Miconazole	Phase 3 (in late-stage trials)
Mineral Oil	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE3	4
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06431542	PHASE4	COMPLETED	Efficacy of Self Vs. Physician Application of Triamcinolone-Econazole in Otomycosis
NCT01993823	PHASE3	COMPLETED	Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
NCT03686384	PHASE3	COMPLETED	SVT-15652 Otic Solution for the Treatment of Otomycosis
NCT03686397	PHASE3	COMPLETED	SVT-15652 Otic Solution for the Treatment of Otomycosis.
NCT04432376	PHASE2/PHASE3	COMPLETED	Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)
NCT05660382	PHASE3	COMPLETED	Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
NCT03130738	PHASE2	COMPLETED	Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis
NCT06339294	PHASE1	COMPLETED	Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment
NCT04768829	EARLY_PHASE1	COMPLETED	Antifungal Potential of Moringa Olifera Against Otomycosis
NCT06530069	Not specified	RECRUITING	Exploring the Risk Factors of Otomycosis: A Case-Control Study
NCT07152327	Not specified	NOT_YET_RECRUITING	Terbinafine Hydrochloride for the Treatment of Otomycosis
NCT01547221	Not specified	COMPLETED	Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients
NCT04824261	Not specified	UNKNOWN	Effectiveness of 4% Boric Acid in Distilled Water Versus Clotrimazole Solution in Otomycosis Patients.
NCT07295210	Not specified	COMPLETED	Boric Acid Versus 10% Povidone Iodine Solution in Treatment of Otomycosis
NCT07535424	Not specified	COMPLETED	Comparative Efficacy of Topical Clotrimazole Versus 2% Salicylic Acid in Otomycosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLOTRIMAZOLE	4	6
MICONAZOLE	4	2
POVIDONE-IODINE	4	2
TERBINAFINE	4	1
BORIC ACID	3	1
CHEMBL173038	0	2
CHEMBL5424182	0	1